Mid-Atlantic BioTherapeutics Overview
- Founded
- 2011
- Status
- Private
- Latest Deal Type
- Angel
- Latest Deal Amount
- $875K
Mid-Atlantic BioTherapeutics General Information
Description
Owner and operator of biotechnology firm intended to eradicate infectious diseases using a novel, patented technology platform. The company's platform addresses the growing antibiotic resistance problems and creating a revolutionary treatment paradigm for viral diseases like Tamiflu alternative for influenza, emerging infectious diseases and biodefense, enabling doctors to provide effective treatment for influenza, creating a powerful alternative to Tamiflu and rabies.
Contact Information
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Primary Office
- 3805 Old Easton Road
- Doylestown, PA 18902
- United States
+1 (215) 000-0000
Mid-Atlantic BioTherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Angel (individual) | 05-Oct-2018 | $875K | 000.00 | Completed | Clinical Trials - Phase 1 | |
| 1. Capitalization | 01-Jan-2018 | 0000 | 0000 | Completed | Clinical Trials - Phase 1 |
Mid-Atlantic BioTherapeutics Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| David Horn MD | Co-Founder & Chief Executive Officer | ||
| Jean-Pierre Gagnon | Co-Founder, Senior Vice President & Board Member |
Mid-Atlantic BioTherapeutics Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Jean-Pierre Gagnon | Mid-Atlantic BioTherapeutics | Co-Founder, Senior Vice President & Board Member | 000 0000 |
| Julian Chick Ph.D | Mid-Atlantic BioTherapeutics | Board Member | 000 0000 |
| Michael Goldblatt Ph.D | Mid-Atlantic BioTherapeutics | Board Member | 000 0000 |